Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25095609 | 0.91 | HTR7 (0.36) | HTR7 | |
| SCHEMBL21933935 | 0.89 | HTR7 (0.33) | HTR7 | |
| SCHEMBL19543661 | 0.86 | HTR7 (0.34) | HTR7 | |
| SCHEMBL11840677 | 0.86 | — | — | |
| SCHEMBL19543019 | 0.86 | HTR7 (0.34) | HTR7 | |
| SCHEMBL12092353 | 0.86 | HTR7 (0.34) | HTR7 | |
| SCHEMBL21933471 | 0.82 | ACHE (0.39) | — | |
| SCHEMBL20314535 | 0.81 | — | — | |
| SCHEMBL18032456 | 0.80 | HTT (0.31) | — | |
| SCHEMBL23277739 | 0.80 | GRIN2D (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018134-A1 | 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2024-01-18 | — | — | US | disclosed |
| US-20240018134-A1 | 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2024-01-18 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| US-8008483-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110152289-A1 | DIMERIC DERIVATIVES OF ARTEMISININ AND APPLICATION IN ANTI-CANCER THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2011-06-23 | — | — | US | disclosed |
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | GLAXOSMITHKLINE LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100311775-A1 | Novel sEH Inhibitors and Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311776-A1 | Novel sEH Inhibitors and their Use | SMITHKLINE BEECHAM CORPORATION | 2010-12-09 | — | — | US | disclosed |
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311776-A1 | Novel sEH Inhibitors and their Use | EPHX1, NCEH1, FAH | HTR7 3070/4885 |
| US-20100311775-A1 | Novel sEH Inhibitors and Their Use | EPHX1, NCEH1, FAH | HTR7 2995/4885 |
| US-20110152289-A1 | DIMERIC DERIVATIVES OF ARTEMISININ AND APPLICATION IN ANTI-CANCER THERAPY | DHFR, THPO, HCCS | HTR7 4198/4885 |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | HTR7 3906/4885 |
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | EPHX1, NCEH1, CYP46A1 | HTR7 2761/4885 |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | PBRM1, SMARCC1, SMARCC2 | HTR7 3848/4885 |
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | EPHX1, NCEH1, PCSK9 | HTR7 3051/4885 |
| US-20240018134-A1 | 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders | SMARCC1, SMARCC2, SMARCA4 | HTR7 1337/4885 |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | HTR7 491/4885 |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC11 | HTR7 3750/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | HTR7 2935/4885 |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | VEGFA, HPGDS, ALOX5 | HTR7 2028/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | HTR7 2708/4885 |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC11 | HTR7 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.